23:59:20 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-04-25 Årsstämma 2025
2025-02-26 Bokslutskommuniké 2024
2024-10-24 Kvartalsrapport 2024-Q3
2024-07-18 Kvartalsrapport 2024-Q2
2024-04-26 Ordinarie utdelning MAGLE 0.35 SEK
2024-04-25 Årsstämma 2024
2024-04-18 Kvartalsrapport 2024-Q1
2024-02-16 Bokslutskommuniké 2023
2023-10-25 Kvartalsrapport 2023-Q3
2023-07-18 Kvartalsrapport 2023-Q2
2023-04-27 Ordinarie utdelning MAGLE 0.00 SEK
2023-04-26 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-17 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning MAGLE 0.00 SEK
2022-05-17 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-25 Bokslutskommuniké 2021
2021-12-14 Extra Bolagsstämma 2021
2021-11-16 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-14 Kvartalsrapport 2021-Q1
2021-05-03 Ordinarie utdelning MAGLE 0.00 SEK
2021-04-18 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-11-27 Extra Bolagsstämma 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-07-14 Kvartalsrapport 2020-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Magle Chemoswed är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom utveckling av analytiska program. Produktportföljen är bred och inkluderar exempelvis program för intern uppföljning, process- samt systemhantering. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster inom arbetsområdet. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Magle Chemoswed har sitt huvudkontor i Malmö.
2022-09-12 08:50:00

Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces the appointment of Helena Ossmer Thedius as Chief Marketing and Innovation Officer. She will be responsible for the global marketing of Magle Group’s proprietary medical products and will also be instrumental in exploiting the company’s cutting-edge material science to further expand the product portfolio.

Helena Ossmer Thedius is a seasoned life-science industry leader who has held various senior roles before joining Magle Group, most recently as Marketing & Innovation Director at the oral health company TePe Oral Hygiene Products, Sweden. Across her career, she has led teams through product development and has been responsible for developing global marketing and brand initiatives and overseeing their implementation. In addition, Helena has experience in various companies and brings a wealth of knowledge as well as an extensive network to her new position at Magle Group.

"Helena Ossmer Thedius has a strong track record of success and her insights and experience are exactly what we need to propel the company forward as we embark on our expansion journey. Helena will be a key person to help us convert our strategic potential into company value for all stakeholders. I am excited to welcome her to the team, and I look forward to us growing the awareness of our brand and medical device products globally," said Justin Pierce, CEO of Magle Group.

I am really excited to be joining Magle Group and bringing my experience of marketing, product development and global product strategies to the team. I see a substantial commercial potential in the company’s current portfolio of unique medical products, which constitutes a solid foundation for its long-term expansion strategy,” comments Helena Ossmer Thedius.

Helena Ossmer Thedius will join Magle Group in late September 2022 and report to CEO Justin Pierce.